Hepatotoxicity of AKR1C3 Inhibitor BAY1128688: Findings from an Early Terminated Phase IIa Trial for the Treatment of Endometriosis

Hepatotoxicity of AKR1C3 Inhibitor BAY1128688: Findings from an Early Terminated Phase IIa Trial for the Treatment of Endometriosis

Abstract Introduction BAY1128688 is a selective inhibitor of aldo-keto reductase family 1 member C3 (AKR1C3), an enzyme implicated in the pathology of endometriosis and other disorders. In vivo animal studies suggested a potential therapeutic application of BAY1128688 in treating endometriosis. Earl...

Full description

Bibliographic Details
Main Authors: Jan Hilpert, Esther Groettrup-Wolfers, Hristiyan Kosturski, Laura Bennett, Catriona L. K. Barnes, Kerstin Gude, Isabella Gashaw, Stefanie Reif, Thomas Steger-Hartmann, Christian Scheerans, Alexander Solms, Antje Rottmann, Guangping Mao, Charles Chapron
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-07-01
Series:Drugs in R&D
Online Access:https://doi.org/10.1007/s40268-023-00427-5

Internet

https://doi.org/10.1007/s40268-023-00427-5

Similar Items